Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Polyunsaturated Fatty Acids, Exercise, and Fatigue in Breast Cancer

2021 Year in Review - Breast Cancer - Breast Cancer

According to several studies, humans developed on a diet with a ratio of omega-6 to omega-3 essential fatty acids of 1, whereas the ratio in Western diets is approximately 15:1. When compared with the diet on which human beings developed and their genetic patterns were established, Western diets are low in omega-3 fatty acids and excessive in omega-6 fatty acids. A ratio of 4:1 was linked to a 70% reduction in total mortality in secondary prevention of cardiovascular disease. In women with breast cancer, a lower omega-6/omega-3 ratio was linked to a lower risk. According to these studies, the ideal ratio varies depending on the condition being studied. Chronic diseases are multigenic and multifactorial, which supports this theory. As a result, it is probable that the therapeutic amount of omega-3 fatty acids will be determined by the severity of sickness caused by a hereditary predisposition. A lower omega-6/omega-3 fatty acid ratio is preferable for reducing the risk for many chronic diseases that are prevalent in Western societies as well as developing countries that export to the rest of the globe.1

Cancer-related fatigue is one of the most common and debilitating symptoms experienced by cancer survivors. It causes substantial degradation in quality of life because of its negative effect on everyday activities, job, social activities, and mood. A recent study surprisingly found that omega-6 polyunsaturated fatty acid (PUFA) supplementation reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation lowered proinflammatory blood markers.2

Meanwhile, a recent meta-analysis of individual patient data demonstrated that exercise therapies have a considerable impact on cancer-related fatigue. In a randomized controlled trial among early-stage Japanese breast cancer survivors in which the effect of baseline blood PUFA characteristics on change in cancer-related fatigue during the 12-week trial by exercise group was studied and confirmed that increased Cancer Fatigue Scale was associated with docosahexaenoic acid and omega-3 index, and that docosahexaenoic acid was positively correlated with change in cancer-related fatigue in the control group.2

Furthermore, in the exercise group, baseline eicosapentaenoic acid was favorably connected with leg strength. The effect of exercise on cancer-related fatigue may be related to blood PUFA balance.2 If there is indeed a link between omega-6 and cancer-related fatigue, then finding the right balance between an increased omega-6 to omega-3 ratio to combat fatigue while not going too high to protect against mortality and cardiovascular disease will be the challenge. Higher essential fatty acid levels in people who exercised are likely to help them build muscle strength. To better understand the interplay between PUFAs and exercise in the treatment of cancer-related fatigue, more research is needed.2

References

  1. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56:365-379.
  2. Matsuoka Y, Tsuji K, Ochi E. Polyunsaturated fatty acids, exercise, and cancer-related fatigue in breast cancer survivors. Front Physiol. 2021;12:759280.
Related Items
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice
February 2022 Clinical Trials to Clinical Practice published on February 3, 2022 in Clinical Trials, Breast Cancer
2021 Breast Cancer Year in Review Introduction
2021 Year in Review - Breast Cancer published on January 21, 2022 in Breast Cancer
Copyright © The Lynx Group, LLC. All rights reserved.